Skip to main content

New evidence reveals tamoxifen reduces breast cancer rates by nearly a third for 20 years

The preventive effect of breast cancer drug ‘tamoxifen’ remains virtually constant for at least 20 years – with rates reduced by around 30 per cent – new analysis published in The Lancet Oncology reveals.  

Published on:
Back to top